De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
De-escalation
Head and neck
Human papillomavirus
Oropharyngeal cancer
Recurrence
Survival
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
22
10
2020
accepted:
17
12
2020
pubmed:
19
2
2021
medline:
6
10
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
Among head and neck squamous cell carcinomas (HNSCCs), oropharyngeal cancer (OPC) was historically thought to be a homogenous entity, mainly caused by excessive alcohol and tobacco consumption. However, the discovery of human papillomavirus (HPV) infection as an independent risk factor for the development of OPC has led to changes in diagnostics and treatment of this cancer. HPV-positive OPC is associated with improved survival and reduced recurrence rates compared to similar stage HPV-negative OPC and HNSCC in general. These favorable outcomes have led the medical and scientific communities to consider de-escalation treatment options in this specific population to spare patients from unnecessary toxicity, without compromising survival. This comment aimed to critically evaluate de-intensification treatment strategies in HPV-related OPC and to propose future treatment approaches as well as trial design. A review of the literature was performed. Among nine published non-surgical de-intensification trials, only three studies had a comparison head-to-head with the standard of care, with two trials demonstrating clear inferiority of de-escalating treatment option (cetuximab-based radiotherapy). Additionally, there has been significant heterogeneity among induction chemotherapy (IC) protocols in de-escalating studies. Also, the toxicity among these studies varies in terms of the manner of reporting (physician vs patient-reported adverse events). Data obtained with de-intensified strategies should only serve to help select an appropriate experimental arm for a randomized controlled trial phase III comparison against cisplatin and 70 Gy of radiotherapy. Without a proper randomized trial, there remains the possibility of compromising survival, which raises ethical questions about conducting any de-escalation trial.
Identifiants
pubmed: 33599841
doi: 10.1007/s00405-021-06686-9
pii: 10.1007/s00405-021-06686-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4599-4603Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB (2006) Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 6:1111–1118
doi: 10.1586/14737140.6.7.1111
Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35
doi: 10.1056/NEJMoa0912217
Bhatia A, Burtness B (2015) Human papillomavirus-associated oropharyngeal cancer: defining risk groups and clinical trials. J ClinOncol 33:3243–3250
doi: 10.1200/JCO.2015.61.2358
Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J et al (2017) Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol 18:803–811
doi: 10.1016/S1470-2045(17)30246-2
Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson JE et al (2018) Mature results of a prospective study of deintensifiedchemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 124:2347–2354
doi: 10.1002/cncr.31338
Chera BS, Amdur RJ, Green R, Shen C, Gupta G, Tan X et al (2019) Phase II trial of deintensifiedchemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. J ClinOncolJco 37:2661
doi: 10.1200/JCO.19.01007
Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S et al (2016) Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose deescalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma. Int J RadiatOncolBiolPhys 96:9–17
Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL et al (2017) E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group. J ClinOncol 35:490–497
doi: 10.1200/JCO.2016.68.3300
Misiukiewicz K, Gupta V, Miles BA, Bakst R, Genden E, Selkridge I et al (2019) Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the quarterback trial. Oral Oncol 95:170–177
doi: 10.1016/j.oraloncology.2019.06.021
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM et al (2019) OPTIMA: a phase II dose and volume de-escalation trial for human papillomaviruspositive oropharyngeal cancer. Ann Oncol 30:297–302
doi: 10.1093/annonc/mdy522
Gillison ML, Trotti AM, Harris J et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393:40–50
doi: 10.1016/S0140-6736(18)32779-X
Mehanna H, Robinson M, Hartley A et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51–60
doi: 10.1016/S0140-6736(18)32752-1
Suton P, Skelin M, Rakusic Z, Dokuzovic S, Luksic I (2019) Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. Eur Arch Otorhinolaryngol 276:1275–1281
doi: 10.1007/s00405-019-05387-8
Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578
doi: 10.1056/NEJMoa053422
Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N (1997) Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. RadiotherOncol 43:29–37
Windon MJ, Fakhry C, Faraji F, Troy T, Gourin CG, Kiess AP (2019) Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment. Oral Oncol 95:11–15
doi: 10.1016/j.oraloncology.2019.05.016
Jones DA, Mistry P, Dalby M et al (2020) Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. Eur J Cancer 124:178–185
doi: 10.1016/j.ejca.2019.10.025
Lee NCJ, Kelly JR, Park HS et al (2018) Patterns of failure in high-metastatic node number human papillomavirus-positive oropharyngeal carcinoma. Oral Oncol 85:35–39
doi: 10.1016/j.oraloncology.2018.08.001
Riaz N, Setton J, Tam M et al (2014) Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. Oral Oncol 50:863–868
doi: 10.1016/j.oraloncology.2014.06.008
O’Sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 17:440–451
doi: 10.1016/S1470-2045(15)00560-4
Mehanna H, Sen M, Chester J (2017) Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE). J ClinOncol 35(15_suppl):1
doi: 10.1200/JCO.2017.35.15_suppl.6004